SCHEMBL1644540

SCHEMBL1644540

B[C@H]1CC(OP(C)(=O)S)[C@@H](COC)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10005841 1.00 — —
SCHEMBL24778339 1.00 — —
SCHEMBL15806353 0.89 — —
SCHEMBL16674741 0.89 — —
SCHEMBL24742681 0.88 — —
SCHEMBL10032931 0.88 — —
SCHEMBL2755679 0.88 — —
SCHEMBL19608787 0.88 — —
SCHEMBL17754507 0.87 — —
SCHEMBL17758834 0.87 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067965-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA INC (US) 2024-02-29 — — US disclosed
US-20230256119-A1 COMPOSITIONS AND METHODS FOR PREPARING AN ALZHEIMER'S DISEASE ANIMAL MODEL USING MICRORNA BIORCHESTRA CO., LTD. (KR) 2023-08-17 — — US disclosed
US-11702652-B2 Enzymatic encoding methods for efficient synthesis of large libraries NUEVOLUTION A/S (DK) 2023-07-18 — — US disclosed
US-20230167502-A1 DIAGNOSTIC METHODS USING MIR-485-3P EXPRESSION BIORCHESTRA CO., LTD. (KR) 2023-06-01 — — US disclosed
US-20230126157-A1 MIRNA-485 INHIBITOR FOR GENE UPREGULATION BIORCHESTRA CO., LTD. (KR) 2023-04-27 — — US disclosed
US-20220143071-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2022-05-12 — — US disclosed
US-20190314401-A1 ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING Neurovision Pharma GmbH (DE) 2019-10-17 — — US disclosed
US-10363266-B2 Antisense-oligonucleotides as inhibitors of TGF-R signaling Neurovision Pharma GmbH (DE) 2019-07-30 — — US disclosed
US-20180161356-A1 TAU ANTISENSE OLIGOMERS AND USES THEREOF ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2018-06-14 — — US disclosed
US-20180112217-A1 Stereospecific Phosphorothioate LNA ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2018-04-26 — — US disclosed
US-20090264300-A1 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S (DK) 2009-10-22 — — US disclosed
US-20090239211-A1 Method For Enrichment Involving Elimination By Mismatch Hybridisation NUEVOLUTION A/S (DK) 2009-09-24 — — US disclosed
US-20090202573-A1 POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES ENZON PHARMACEUTICALS, INC. (US) 2009-08-13 — — US disclosed
US-20090203137-A1 COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION SANTARIS PHARMA A/S (DK) 2009-08-13 — — US disclosed
US-20090181916-A1 LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR SANTARIS PHARMA A/S (DK) 2009-07-16 — — US disclosed
US-20090143232-A1 METHOD FOR SYNTHESISING TEMPLATED MOLECULES NUEVOLUTION A/S (DK) 2009-06-04 — — US disclosed
US-20090118213-A1 RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION SANTARIS PHARMA A/S (DK) 2009-05-07 — — US disclosed
US-7413854-B2 Method for synthesising templated molecules NUEVOLUTION A/S (DK) 2008-08-19 — — US disclosed
US-20080188432-A1 Short nucleotide subsequences located within number 15; such as locked nucleic acids antisense oligonucleotides; biostability, cell permeability; anticancer agents SANTARIS PHARMA A/S (DK) 2008-08-07 — — US disclosed
US-20070026397-A1 Method for producing second-generation library NUEVOLUTION A/S (DK) 2007-02-01 — — US disclosed
Send feedback